» Articles » PMID: 10404762

Long-term Management of Homozygous Protein C Deficiency: Replacement Therapy with Subcutaneous Purified Protein C Concentrate

Overview
Journal Thromb Haemost
Publisher Thieme
Date 1999 Jul 15
PMID 10404762
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We present the case of a full-term newborn in whom purpura fulminans developed shortly after birth. A diagnosis of homozygous protein C deficiency was established based upon undetectable plasma protein C activity and antigenemia in the newborn infant, and was later confirmed by protein C gene analysis. Specific replacement therapy with intravenous protein C concentrate was started 9 days after birth. This rapidly led to the complete regression of cutaneous lesions and consumption coagulopathy. After stabilization, oral anticoagulation was initiated in association with prophylactic treatment with intravenous protein C concentrate. However, oral anticoagulation was finally abandoned as the patient presented several thrombotic and hemorrhagic episodes clearly related to difficulties with anticoagulation. Due to the hazards related to prolonged venous access, we are currently using subcutaneous infusion of protein C concentrate for the long-term management of this condition, with satisfactory results.

Citing Articles

Comprehensive literature review of protein C concentrate use in patients with severe congenital protein C deficiency.

Siffel C, Wadhwa A, Tongbram V, Ogongo M, Sliwka H, Gazda H Res Pract Thromb Haemost. 2024; 8(6):102542.

PMID: 39286606 PMC: 11403366. DOI: 10.1016/j.rpth.2024.102542.


[Fulminant purpura caused by hereditary protein C deficiency: two cases and literature review].

Duan Y, Wu Y, Xu Y, Tong W, Jin D Zhonghua Xue Ye Xue Za Zhi. 2023; 43(12):1043-1045.

PMID: 36709112 PMC: 9939334. DOI: 10.3760/cma.j.issn.0253-2727.2022.12.012.


Case Report: Successful Long-Term Management of a Low-Birth Weight Preterm Infant With Compound Heterozygous Protein C Deficiency With Subcutaneous Protein C Concentrate Up to Adolescence.

Poschl J, Behnisch W, Beedgen B, Kuss N Front Pediatr. 2021; 9:591052.

PMID: 34650936 PMC: 8506145. DOI: 10.3389/fped.2021.591052.


Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency.

Kroiss S, Albisetti M Biologics. 2010; 4:51-60.

PMID: 20376174 PMC: 2846144. DOI: 10.2147/btt.s3014.


Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Knoebl P Biologics. 2009; 2(2):285-96.

PMID: 19707361 PMC: 2721356. DOI: 10.2147/btt.s1954.